S. A. Lukyanov

S. A. Lukyanov

Auto-generated profile, based on publicly available information

S. A. Lukyanov

Institute of Translational Medicine, Pirogov Russian National Research Medical University, 117513, Moscow, Russia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2025 in Doklady Biochemistry and Biophysics
Verified
Journal Article
Closed access
PDF file
ENE. L. Nasonov
E. L. Nasonov
VMV. I. Mazurov
V. I. Mazurov
ALAleksandr M Lila
Aleksandr M Lila
TDT. V. Dubinina
T. V. Dubinina
IGI. Z. Gaidukova
I. Z. Gaidukova
GVG. A. Vinderskaya
G. A. Vinderskaya
The study aims to evaluate the clinical efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of seniprutug (BCD-180) in patients with active radiographic axial spondyloarthritis (r-axSpA, or ankylosing spondylitis). . Two hundred sixty patients with active r-axSpA and inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs) were randomized into three groups to receive either seniprutug (BCD-180) 5 or 7 mg/kg, or placebo. BCD-180 was administered in the respective group dose using a 0–12–36 week regimen. The placebo group patients were switched to BCD-180 5 mg/kg at Week 24, with therapy continued at Week 36. The primary endpoint was the proportion of patients achieving 40% improvement in the Assessment in Spondyloarthritis International Society (ASAS40) score at Week 24. The secondary endpoints included the proportion of patients achieving an ASAS20/40 response, improvement in 5 of 6 ASAS criteria (ASAS5/6), partial remission according to ASAS, ASDAS-CRP clinically important improvement in (Ankylosing Spondylitis Disease Activity Score with C-reactive protein level, ASDAS-CII) and ASDAS-CRP major improvement (ASDAS-MI). An analysis of changes over time in the disease activity status according to ASDAS-CRP, BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and BASFI (Bath Ankylosing Spondylitis Functional Index) scores, as well as changes over time in laboratory markers (CRP and erythrocyte sedimentation rate (ESR)) was also conducted. Safety was assessed based on the frequency and profile of adverse events (AE) and adverse reactions (AR). The proportion of patients who achieved an ASAS40 response at Week 24 on seniprutug (BCD-180) at doses of 7 and 5 mg/kg was 51.4 and 40.8%, respectively, compared with 24% in the Placebo group (p = 0.0012 and p = 0.0417, respectively). Analysis of secondary endpoints showed that the efficacy of BCD-180 at both study doses was statistically significantly superior to placebo in patients with r-axSpA at Week 24 in the following respects: reduction in the proportion of subjects with very high disease activity (ASDAS-CRP > 3.5), achieving ASDAS-CII, ASAS20, ASAS5/6 response. A statistically significant decrease in the ASDAS-CRP, BASDAI, BASFI score, as well as CRP and ESR levels was demonstrated. Tolerability of seniprutug therapy was assessed as acceptable. The most common AEs were infusion-related reactions, most of which were mild to moderate according to CTCAE 5.0 (Common Terminology Criteria for Adverse Events) and developed mainly during the first administration. The proportion of patients with detected binding antibodies was 5.1%. No neutralizing antibodies were detected. . Seniprutug (BCD-180) as a therapy for r-axSpA has demonstrated superiority over placebo in the clinical efficacy, a good safety profile and low immunogenicity.

4 December 2018 in Bulletin of Russian State Medical University
Verified
Journal Article
Open access
MIMa Israelson
Ma Israelson
ASAv Stepanov
Av Stepanov
DSDmitry Staroverov
Dmitry Staroverov
ISIa Shagina
Ia Shagina
AMAlexey Misorin
Alexey Misorin
SLSa Lukyanov
Sa Lukyanov
In the last decade there has been a tendency to move away from the symptomatic treatment and embrace targeted therapies. This process is underpinned by the accumulated knowledge of the mechanisms underlying the pathogenesis of diseases and driven by the advances in biotechnologies. T-cell receptors with variable TRBV9 β-chain regions have been recently associated with spondyloarthritis including its subtype, ankylosing spondylitis. The aim of this work was to engineer a chimeric monoclonal antibody targeting the variable region of the T-cell receptor β-chain encoded by the TRBV9 gene segment and assess its specificity and cytotoxicity. Using flow cytometry and next generation sequencing, we demonstrate that the engineered chimeric antibody is highly specific and exhibits cytotoxic activity against its target. Approaches based on the use of therapeutic chimeric antibodies against pathogenic T-clones may hold great promise for the therapy of autoimmune disorders in general and AS in particular.

16 June 2024 in Modern Rheumatology Journal
Verified
Journal Article
Open access
PDF file
ALAleksandr M Lila
Aleksandr M Lila
VMV. I. Mazurov
V. I. Mazurov
ENE. L. Nasonov
E. L. Nasonov
SLS. A. Lukyanov
S. A. Lukyanov
TDT. V. Dubinina
T. V. Dubinina
NSN. V. Shatalova
N. V. Shatalova
On 30 May, 2024, an expert meeting was held to update the approaches for the treatment of axial spondyloarthritis (axSpA). A new approach to the treatment of axSpA was considered, which consists of depleting autoreactive TRBV9+ T- lymphocytes by introducing a monoclonal antibody – the drug seniprutug. The value of the drug seniprutug in the treatment of the disease was discussed and key aspects for the incorporation of the drug seniprutug into real-world clinical rheumatological practice were agreed.

21 April 2023 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
DCD.M. Chudakov
D.M. Chudakov
EPE.E. Petryaykina
E.E. Petryaykina
EDE.S. Demina
E.S. Demina
SLS.A. Lukyanov
S.A. Lukyanov
ATA.V. Timofeev
A.V. Timofeev
Type 1 diabetes mellitus (DM1) is a world- and widespread disease in children and adolescents caused by the destruction of insulin-producing β-cells in the pancreas. As of today there is only one generally accepted approach to treating DM1, which is the insulin therapy, which in fact is a symptomatic therapy since it is aimed at correcting the outcome of the DM1 pathogenesis through compensation of insulin deficiency and elimination of hyperglycemia. The insulin therapy makes it possible to maintain the acceptable blood glucose levels for decades, but does not prevent the development of severe chronic complications of DM1, which in its turn are the main causes for disability cases and early deaths in such patients. Practitioners and scientists in diabetology are therefore actively searching for the ways to treating DM1 etiologically and pathogenetically. Among such methods there are various promising variants of immunotherapy aimed at prevention or suppression of an autoimmune reaction against β-cells. This review provides the basic information on DM1 and considers the modern approaches to its immunotherapy. The particular attention is paid to immunotherapy using cytotoxic monoclonal antibodies against B-lymphocytes autoreactive towards β-cells.

27 December 2025 in bioRxiv
Verified
Preprint
Open access
NNN.A. Nikolaev
N.A. Nikolaev
MMM.YU. Myshkin
M.YU. Myshkin
EKE.A Kolobova
E.A Kolobova
ISI.A. Shagina
I.A. Shagina
OKO.I. Kechko
O.I. Kechko
OBOlga Britanova
Olga Britanova
Computational approaches are increasingly used to predict monoclonal antibody (mAb) candidates from BCR-seq datasets. However, the reliable identification of B cells encoding antibodies against rare antigenic epitopes remains challenging. We employed a repertoire-guided workflow combining antigen-tetramer sorting of B cells from immunized mice, followed by low-input bulk BCR-seq yielding informative clonal repertoires. Clustering and supporting somatic hypermutation (SHM) lineage analysis allowed us to identify IGH and IGK clonotypes potentially targeting β–amyloid and its isoAsp7 variant (isoD7–Aβ1-16), implicated in Alzheimer′s disease. We observed recurrent IGHV8-12 and IGKV1-117 usage, consistent with canonical mouse anti-Aβ responses. Focusing on isoD7–Aβ binders, we selected ten candidate IGH—IGK pairs for recombinant expression. One recombinant mAb demonstrated preferential binding to isoD7–Aβ by microscale thermophoresis, supporting the feasibility of the approach but underscoring the challenge of accurate chain pairing. This highlights the potential of bioinformatic workflows to identify mAbs even under low-input conditions.

1 April 2018 in Bulletin of Russian State Medical University
Verified
Journal Article
Open access
EKE.A. Komech
E.A. Komech
YLY.B. Lebedev
Y.B. Lebedev
AKA.V. Koshenkova
A.V. Koshenkova
DSD.S. Syrko
D.S. Syrko
EME.A. Musatkina
E.A. Musatkina
IZI.V. Zvyagin
I.V. Zvyagin